Diagnostik und Therapie der Vaginalatrophie bei Patientinnen mit Mammakarzinom

M. Moegele; C. Lattrich; S. Seitz; S. Buchholz; O. Ortmann

doi:10.1055/s-0032-1315086

Frauenheilkunde up2date, Table of Contents

Frauenheilkunde up2date 2012; 6(4): 194-198
DOI: 10.1055/s-0032-1315086

Forum

Georg Thieme Verlag KG Stuttgart · New York

Diagnostik und Therapie der Vaginalatrophie bei Patientinnen mit Mammakarzinom

M. Moegele

,

C. Lattrich

,

S. Seitz

,

S. Buchholz

,

O. Ortmann

Abstract

All articles of this category

Full Text

References

Literatur
1 Robert-Koch-Institut. Krebs in Deutschland 2005/2006, Häufigkeit und Trends. 7. Ausgabe Berlin: Robert-Koch-Institut; 2010
2 Ortmann O, Emons G, Fasching PA et al. Das klimakterische Syndrom der Patientin mit Mammakarzinom: Risiken und Nutzen der Behandlungsoptionen. Geburtsh Frauenheilk 2007; 67: R53-R72
3 Cella D, Fallowfield LJ. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat 2008; 107: 167-180
4 Ortmann O, Dören M, Windler E. Hormone therapy in perimenopause and postmenopause (HT): Interdisciplinary S3 guideline. Association of the Scientific Medical Societies in Germany AWMF 015/062-short version. Arch Gynecol Obstet 2011; 284: 343-355
5 Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997; 350: 1047-1059
6 Ravdin PM, Cronin KA, Howlader N. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007; 356: 1670-1674
7 Col N, Hirota L et al. Hormone replacement therapy after breast cancer: a systemic review and quantitative assessment of risk. J Clin Oncol 2001; 19: 2357-2363
8 Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancer – is it safe?), a randomised comparison: trial stopped. Lancet 2004; 363: 453-455
9 von Schoultz E, Rutqvist LE. Menopausal hormone therapy after breast cancer: The Stockholm randomized trial. J Natl Cancer Inst 2005; 97: 533-535
10 Beral V. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419-427 Erratum in: Lancet 2003; 362: 1160
11 Kenemans P, Bundred NJ et al. LIBERATE Study Group. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomized, non inferiority trial. Lancet Oncol 2009; 10: 135-146
12 Graziottin A. Sexuality in the menopause. In: Studd J. The Yearbook of Royal College of Obstetrics and Gynecologists. London: RCOG Press; 1997: 201-209
13 Simon JA, Komi J. Vulvovaginal atrophy negatively impacts sexual function, psychosocial wellbeing, and partner relationships. N Am Menopause Assoc 2007; 10: 3-6
14 Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2003; (4) CD001500
15 Ortmann O, Lattrich C. The treatment of climacteric symptoms. Dtsch Arztebl Int 2012; 109: 316-324
16 Weisberg E, Ayton R, Darling G. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric 2005; 8: 83-92
17 Kendall A, Dowsett M, Folkerd E et al. Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 2006; 17: 584-587
18 Dew JE, Wren BG, Eden JA. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric 2003; 6: 45-52
19 Pfeiler G, Glatz C, Königsberg R. Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients. Climacteric 2011; 14: 339-344
20 Mattsson LA, Cullberg G. Vaginal absorption of two estriol preparations. A comparative study in postmenopausal women. Acta Obstet Gynecol Scand 1983; 62: 393-396
21 Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas 1996; 23: 259-263
22 Biglia N, Peano E, Sgandurra P. Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecol Endocrinol 2010; 26: 404-412